Printer Friendly

Steroid induced pathological fractures.

Multiple Sclerosis (MS) is a chronic inflammatory autoimmune disease that attacks the central nervous system (CNS) resulting in destruction of myelin and neuronal death. It is the leading cause of neurological disability in young adults ages 20-40. This progressive and degenerative disease is characterized by periods of remission and exacerbation. In an effort to slow progression of the disease or treat an exacerbation, it is standard practice for physicians to administer steroid therapy to suppress the autoimmune response. The administration of large doses of corticosteroids over an extended period of several years can have long-term complications, which may not be evident until many years after the administration of the drug. A case study of a 60-year-old white female demonstrates the complication of steroid induced osteoporosis that resulted in three pathological fractures ten years after receiving steroid therapy.

Melinda Redmon, College of Nursing, Univ. of Ala., Huntsville, AL 35899.
COPYRIGHT 2003 Alabama Academy of Science
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Health Sciences
Author:Redmon, Melinda
Publication:Journal of the Alabama Academy of Science
Article Type:Brief Article
Date:Apr 1, 2003
Words:148
Previous Article:Bological properties of some 3,4-dialkyl-4-aza-cholestanes.
Next Article:Knowledge, resilience and effectiveness of a Young Teen Asthma Camp.
Topics:


Related Articles
Analysis of 1-year vertebral fracture risk reduction data in treatments for osteoporosis. (Review Article).
Women benefit from low dose of estrogen.
Drugs and sports.
Bone builder: drug may offer steroid users new protection against fractures.
Zinc L-carnosine guards against NSAID damage.
Exercise and women's health; new research.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters